

Medical Coverage Policy | Cryosurgical Ablation of Primary or Metastatic Liver Tumors



EFFECTIVE DATE: 02|17|2015

POLICY LAST UPDATED: 12|06|2016

OVERVIEW

Cryosurgical ablation involves the freezing of target tissues, most often by inserting into the tumor a probe through which coolant is circulated. Cryosurgical ablation can be performed as an open surgical technique or percutaneously or laparoscopically, typically with ultrasound guidance.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercial

Cryosurgical ablation of either primary or metastatic tumors in the liver is not medically necessary as there is a lack of peer reviewed scientific evidence to support its efficacy.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND

Hepatic tumors can arise either as primary liver cancer or by metastasis to the liver from other tissues. Local therapy for hepatic metastasis is indicated only when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma (CRC) or certain neuroendocrine malignancies. At present, surgical resection with tumor-free margins or liver transplantation represent the only treatments with curative potential. For liver metastases from CRC, postsurgical adjuvant chemotherapy has been reported to decrease recurrence rates and prolong time to recurrence. However, most hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve. Combined systemic and hepatic arterial chemotherapy may increase disease-free intervals for patients with hepatic metastases from CRC but apparently is not beneficial for those with unresectable HCC.

Various locoregional therapies for unresectable liver tumors are being studied: cryosurgical ablation (cryosurgery), RFA, laser ablation, transhepatic artery embolization/ chemoembolization, microwave coagulation, and percutaneous ethanol injection. Ablation occurs in tissue that has been frozen by at least 3 mechanisms: (1) formation of ice crystals within cells, thereby disrupting membranes and interrupting cellular metabolism among other processes; (2) coagulation of blood, thereby interrupting blood flow to the tissue, in turn causing ischemia and cell death; and (3) induction of apoptosis (cell death). Recent studies report experience with cryosurgical and other ablative methods used in combination with subtotal resection and/or procedures such as transarterial chemoembolization

Most patients in published series were candidates for cryosurgery because of unresectable disease, due either to large number of metastases, inaccessible location (eg, near large vessels), or insufficient hepatic reserve to support resection. However, some of the studies included patients with resectable tumors, as well as patients

with unresectable tumors. Furthermore some studies pooled results for mixed series of patients with liver metastases from various noncolorectal cancers (eg, breast, sarcoma, ovarian, testicular, pancreatic, esophageal, head and neck), despite the differing characteristics and prognoses of these malignancies. Few controlled studies were found and most had methodologic weaknesses including lack of randomization and noncomparable groups. In 1 randomized controlled trial that compared cryosurgery with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), rates of tumor progression, survival, and complications were comparable between groups. However, further studies are needed to confirm these results. Therefore, published outcomes of cryosurgery are inconclusive. The recent literature provides little new information on cryosurgical techniques, and interest appears to be concentrated on RFA. Thus, cryoablation for primary or metastatic liver tumors is **not medically necessary**

CODING

Blue CHIP for Medicare and Commercial

The following cpt codes are not medically necessary

47371 Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical

47381 Ablation, open, 1 or more liver tumor(s); cryosurgical

47383 Ablation, 1 or more liver tumor(s), percutaneous, cryoablation (new code as of 01/01/15)

RELATED POLICIES

None

PUBLISHED

Provider Update, January 2017

Provider Update, April 2015

Provider Update, August 2011

Provider Update, Dec 2010

Provider Update, May 2008

REFERENCES:

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Cryosurgical Ablation of Unresectable Hepatic Tumors. TEC Assessments 2000; Volume 15, Tab 14.
2. Wang C, Wang H, Yang W, et al. A multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. *Hepatology*. Oct 6 2014. PMID 25284802
3. Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. *Ann Surg Oncol*. Apr 2015;22(4):1294-1300. PMID 25287439
4. Dunne RM, Shyn PB, Sung JC, et al. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: a comparison of the safety of cryoablation and radiofrequency ablation. *Eur J Radiol*. Apr 2014;83(4):632-638. PMID 24529593
5. Awad T, Ghorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. *Cochrane Database Syst Rev*. 2009(4):CD007611.
6. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. *Arch Surg*. 2002;137(12):1332-1339. PMID
7. Yang Y, Wang C, Lu Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci*. Dec 21 2012;19(6):674-684. PMID 22187145
8. Rong G, Bai W, Dong Z, et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. *PLoS One*. 2015;10(4):e0123065. PMID 25849963
9. Zhou L, Yang YP, Feng YY, et al. Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. *Chin J Cancer*. 2009;28(1):45-48.

10. Wang C, Lu Y, Chen Y, et al. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. *Clin Exp Metastasis*. 2009;26(7):839-848. PMID
11. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenterohepatic neuroendocrine tumors: safe hepatic surgery. *World J Surg*. 2001;25(6):689-692.
12. Gurusamy KS, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours in patients with respectable liver metastases. *Cochrane Database Syst Rev*. 2009(2):CD0076060.
13. Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. *Am J Clin Oncol*. Oct 2012;35(5):439-445. PMID 21654315
14. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. *Surgery*. 2001;130(6):954-962.
15. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. *Cochrane Database Syst Rev*. 2008(2):CD006039.
16. Korpan NN. Hepatic cryosurgery for liver metastases: long term follow-up. *Ann Surg*. 1997;225(2):193-201.
17. Bala MM, Riemsma RP, Wolff R, et al. Cryotherapy for liver metastases. *Cochrane Database Syst Rev*. 2013;6:CD009058. PMID 23740609
18. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. *Colorectal Dis*. Sep 2011;13(9):e252-265. PMID 21689362
19. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. *Ann Surg Oncol*. 2007;14(3):1161-1169.
20. Niu R, Yan TD, Zhu JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. *Ann Surg Oncol*. 2007;14(7):2078-2087.
21. Joosten J, Jager G, Oyen W, et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. *Eur J Surg Oncol*. 2005;31(10):1152-1159.
22. Ng KM, Chua TC, Saxena A, et al. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. *Ann Surg Oncol*. Apr 2012;19(4):1276-1283. PMID 21913018
23. Seifert JK, Springer A, Baier P, et al. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. *Int J Colorectal Dis*. 2005;20(6):507-520.
24. Kornprat P, Jarnagin WR, DeMatteo RP, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. *Arch Surg*. 2007;142(11):1087-1092.
25. Xu KC, Niu LZ, He WB, et al. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. *World J Gastroenterol*. 2008;14(9):1430-1436.
26. Sohn RL, Carlin AM, Steffes C, et al. The extent of cryosurgery increases the complication rate after hepatic cryoablation. *Am Surg*. 2003;69(4):317-322.
27. National Comprehensive Cancer Network. Hepatobiliary Cancers, Version 2.2015. NCCN Clinical Practice Guidelines in Oncology 2015; www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. Accessed November 17, 2015.
28. National Comprehensive Cancer Network. Neuroendocrine Tumors, Version 1.2015. NCCN Clinical Practice Guidelines in Oncology 2015; http://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf. Accessed November 17, 2015.
29. National Comprehensive Cancer Network. Colon Cancer, version 1.2016. Clinical Practice Guidelines in Oncology 2016; http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed November 17, 2015.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

